文献速递心脑血管急症重症综合管理与镇静镇痛

重型创伤性脑损伤伴阵发性交感神经过度兴奋患者的 心率变异性与脑自动调节

Heart Rate Variability and Cerebral Autoregulation in Patients with Traumatic Brain Injury with Paroxysmal Sympathetic Hyperactivity Syndrome.
PubMed 文献 · Neurocrit Care · 2024-10-29
一句话结论在重型颅脑损伤患者中,低频心率变异性升高和心率降低可能早期预测阵发性交感神经过度兴奋综合征,尤其是弥漫性轴索损伤患者。

这项单中心回顾性研究分析了66例重型创伤性脑损伤患者,监测伤后5天动脉血压和颅内压信号,计算心率变异性时域和频域指标及压力反应指数评估脑自动调节。结果9例确诊阵发性交感神经过度兴奋综合征(PSH)。PSH患者低频功率更高(253±178 vs 176±227 ms²,p=0.035)、心率更低(70±7 vs 78±19 bpm,p=0.027)。ROC曲线显示心率(AUC=0.73,p=0.006)和低频心率变异性(AUC=0.70,p=0.009)对PSH有中等预测价值。多因素logistic回归中弥漫性轴索损伤(OR=10.82,95%CI 1.70-68.98,p=0.012)和心率(OR=0.91,95%CI 0.84-0.98,p=0.021)是显著因素。作者认为低频心率变异性升高和心率降低可能作为PSH的早期预测指标,尤其适用于弥漫性轴索损伤患者,但需进一步研究脑自动调节与自主神经系统关系在PSH预后中的效用。

要点

  • 重型创伤性脑损伤后5天内,PSH患者低频心率变异性更高(253±178 vs 176±227 ms²,p=0.035)、心率更低(70±7 vs 78±19 bpm,p=0.027)。
  • 心率(AUC=0.73,p=0.006)和低频心率变异性(AUC=0.70,p=0.009)对PSH有中等预测价值。
  • 多因素logistic回归显示弥漫性轴索损伤(OR=10.82,95%CI 1.70-68.98,p=0.012)和心率(OR=0.91,95%CI 0.84-0.98,p=0.021)与PSH显著相关。
  • PSH患者脑自动调节受损比例67%,无PSH患者72%。
  • 作者认为低频心率变异性升高和心率降低可能作为PSH早期预测指标,尤其弥漫性轴索损伤患者,需进一步研究。

适用人群与场景

  • 重型创伤性脑损伤患者,伤后5天内监测动脉血压和颅内压信号。

研究设计与关键结果

  • 单中心回顾性研究,纳入66例重型创伤性脑损伤患者(中位年龄33[四分位距26-50]岁),9例确诊PSH。
  • PSH患者低频心率变异性为253±178 ms²,无PSH患者为176±227 ms²(p=0.035);PSH患者心率70±7 bpm,无PSH患者78±19 bpm(p=0.027)。
  • 脑自动调节受损在PSH患者中占67%,在无PSH患者中占72%。
  • ROC曲线分析:心率预测PSH的AUC=0.73(p=0.006),低频心率变异性预测PSH的AUC=0.70(p=0.009)。
  • 多因素logistic回归:弥漫性轴索损伤OR=10.82(95%CI 1.70-68.98,p=0.012),心率OR=0.91(95%CI 0.84-0.98,p=0.021)。

证据类型、等级与局限

  • 证据类型:单中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为低频心率变异性升高和心率降低可能作为PSH综合征的早期预测指标,尤其适用于弥漫性轴索损伤患者。
  • 作者指出需进一步研究脑自动调节与自主神经系统关系在PSH预后中的效用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Severe traumatic brain injury (TBI) can lead to transient changes in autonomic nervous system (ANS) functioning and development of paroxysmal sympathetic hyperactivity (PSH) syndrome. Clinical manifestation of ANS disorders may be obscured by therapeutic interventions in TBI. This study aims to analyze ANS metrics and cerebral autoregulation in patients with PSH syndrome to determine their significance in early prognostication.

METHODS: This single-center retrospective study investigated the relationship between changes in ANS metrics, cerebral autoregulation, and PSH syndrome. Arterial blood pressure and intracranial pressure signals were monitored for 5 days post TBI. ANS metrics included time and frequency domain heart rate variability (HRV) metrics. Cerebral autoregulation was assessed using the pressure reactivity index.

RESULTS: Sixty-six patients with severe TBI (median age 33 [interquartile range 26-50] years) were analyzed, and PSH was confirmed in nine cases. Impairment of cerebral autoregulation was observed in 67% of patients with PSH and 72% without the syndrome. Patients with PSH had higher HRV in the low-frequency range (LF; 253 ± 178 vs. 176 ± 227 ms2; p = 0.035) and lower heart rates (HRs; 70 ± 7 vs. 78 ± 19 bpm; p = 0.027) compared to those without PSH. A receiver operating characteristic curve analysis indicated that HR (area under the curve (AUC) = 0.73, p = 0.006) and HRV in the LF (AUC = 0.70, p = 0.009) are moderate predictors of PSH. In the multiple logistic regression model for PSH, diffuse axonal trauma (odds ratio (OR) = 10.82, 95% confidence interval (CI) = 1.70-68.98, p = 0.012) and HR (OR = 0.91, 95% CI 0.84-0.98, p = 0.021) were significant factors.

CONCLUSIONS: Elevated HRV in the LF and decreased HR may serve as early predictors of PSH syndrome development, particularly in patients with diffuse axonal trauma. Further research is needed to investigate the utility of the cerebral autoregulation-ANS relationship in PSH prognostication.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Burzyńska M, Woźniak J, Urbański P, et al. Heart Rate Variability and Cerebral Autoregulation in Patients with Traumatic Brain Injury with Paroxysmal Sympathetic Hyperactivity Syndrome. Neurocrit Care. 2024. PMID: 39470966. doi:10.1007/s12028-024-02149-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。